Abstract: OBJECTIVE To investigate the characteristics of adverse drug reactions(ADR) induced by iodine contrast agent in coronary interventional therapy, and to provide reference for its rational use. METHODS Patients who underwent percutaneous coronary intervention from January 2011 to December 2018 and ADRs induced by iodine contrast agent in percutaneous coronary intervention during this period in the First Hospital Affiliated to Soochow University were enrolled for the study. The demographic characteristics of patients, types of iodine contrast agent, severity of ADR, time of occurrence, involved systems, clinical manifestations and outcomes were analyzed respectively. RESULTS The patients who used iodixanol, iohexol, iodophor and iopromide were 4 631, 7 074, 13 058 and 66, respectively. Seventy one cases of ADR were reported during this period and the incidence rate was 2.9‰. Of which, 64 cases(90.1%) were delayed ADR and 7 cases(9.9%) were after secondary use. Five cases(7.0%) with severe and 66 cases(93.0%) with general. There was no significant difference in gender(P=0.221), age(P=1.000), previous allergy history(P=0.460), type of iodine contrast agent(P=0.427) and outcome(P=1.000), but the proportion of acute ADRs in severe was significantly higher than that in general(P<0.001). Of these ADRs, 63 cases(81.8%) involved mucocutaneous system, followed by 6 cases with urinary system(7.8%) and 5 cases with digestive system(6.5%) involved urinary system and digestive system, respectively. All ADRs had a good outcome after symptomatic treatment. CONCLUSION The ADR induced by iodine contrast agent in coronary interventional therapy is mainly involved mucocutaneous system. As it is more common to have delayed reactions, the clinical may need to extend the observation time of ADR, and even if the patient does not have ADR after the initial use, the focus on ADR should also be strengthened in the subsequent use.